These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Elevated serum levels of bone sialoprotein (BSP) predict long-term mortality in patients with pancreatic adenocarcinoma. Loosen SH; Hoening P; Puethe N; Luedde M; Spehlmann M; Ulmer TF; Cardenas DV; Roy S; Tacke F; Trautwein C; Neumann UP; Luedde T; Roderburg C Sci Rep; 2019 Feb; 9(1):1489. PubMed ID: 30728413 [TBL] [Abstract][Full Text] [Related]
4. Normalization of CA19-9 following resection for pancreatic ductal adenocarcinoma is not tantamount to being cured? Chen T; Zhang MG; Yu XJ; Liu L Asian Pac J Cancer Prev; 2015; 16(2):661-6. PubMed ID: 25684504 [TBL] [Abstract][Full Text] [Related]
5. Serum platelet factor 4 is an independent predictor of survival and venous thromboembolism in patients with pancreatic adenocarcinoma. Poruk KE; Firpo MA; Huerter LM; Scaife CL; Emerson LL; Boucher KM; Jones KA; Mulvihill SJ Cancer Epidemiol Biomarkers Prev; 2010 Oct; 19(10):2605-10. PubMed ID: 20729288 [TBL] [Abstract][Full Text] [Related]
6. Pre-operative Plasma miR-21-5p Is a Sensitive Biomarker and Independent Prognostic Factor in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgical Resection. Karasek P; Gablo N; Hlavsa J; Kiss I; Vychytilova-Faltejskova P; Hermanova M; Kala Z; Slaby O; Prochazka V Cancer Genomics Proteomics; 2018; 15(4):321-327. PubMed ID: 29976637 [TBL] [Abstract][Full Text] [Related]
7. Identification of a novel serum biomarker for pancreatic cancer, C4b-binding protein α-chain (C4BPA) by quantitative proteomic analysis using tandem mass tags. Sogawa K; Takano S; Iida F; Satoh M; Tsuchida S; Kawashima Y; Yoshitomi H; Sanda A; Kodera Y; Takizawa H; Mikata R; Ohtsuka M; Shimizu H; Miyazaki M; Yokosuka O; Nomura F Br J Cancer; 2016 Oct; 115(8):949-956. PubMed ID: 27657339 [TBL] [Abstract][Full Text] [Related]
8. Survivin expression and serum levels in pancreatic cancer. Dong H; Qian D; Wang Y; Meng L; Chen D; Ji X; Feng W World J Surg Oncol; 2015 May; 13():189. PubMed ID: 26016480 [TBL] [Abstract][Full Text] [Related]
9. Clinical significance of serum carbohydrate antigen 19.9 and duke pancreatic monoclonal antigen type 2 for the prediction of hematogenous metastases in patients with pancreatic ducal adenocarcinoma. Kurahara H; Maemura K; Mataki Y; Sakoda M; Iino S; Arigami T; Mori S; Ueno S; Shinchi H; Takao S; Natsugoe S Pancreatology; 2016; 16(6):1051-1056. PubMed ID: 27693096 [TBL] [Abstract][Full Text] [Related]
10. Preoperative neutrophil-to-lymphocyte ratio as a prognosticator in early stage pancreatic ductal adenocarcinoma. Abe T; Amano H; Kobayashi T; Hanada K; Nakahara M; Ohdan H; Noriyuki T Eur J Surg Oncol; 2018 Oct; 44(10):1573-1579. PubMed ID: 29807728 [TBL] [Abstract][Full Text] [Related]
11. Serum levels of kisspeptin are elevated in critically ill patients. Luedde M; Spehlmann ME; Hippe HJ; Loosen SH; Roy S; Vargas Cardenas D; Vucur M; Frey N; Koch A; Luedde T; Trautwein C; Tacke F; Roderburg C PLoS One; 2018; 13(10):e0206064. PubMed ID: 30332461 [TBL] [Abstract][Full Text] [Related]
12. Postoperative peripheral absolute blood lymphocyte-to-monocyte ratio predicts therapeutic outcome after pancreatic resection in patients with pancreatic adenocarcinoma. Fujiwara Y; Misawa T; Shiba H; Shirai Y; Iwase R; Haruki K; Furukawa K; Futagawa Y; Yanaga K Anticancer Res; 2014 Sep; 34(9):5163-8. PubMed ID: 25202109 [TBL] [Abstract][Full Text] [Related]
14. Analysis of Blood Plasma MicroRNAs to Enable Identification of Patients with Pancreatic Ductal Adenocarcinoma Who Will Benefit from Surgical Resection. Gablo N. A; Procházka V; Hlavsa J; Kiss I; Srovnal J; Kala Z; Slabý O Klin Onkol; 2019; 32(Suppl 1):174-176. PubMed ID: 31064193 [TBL] [Abstract][Full Text] [Related]
15. CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time. Rieser CJ; Zenati M; Hamad A; Al Abbas AI; Bahary N; Zureikat AH; Zeh HJ; Hogg ME Ann Surg Oncol; 2018 Nov; 25(12):3483-3491. PubMed ID: 29786131 [TBL] [Abstract][Full Text] [Related]
16. Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma. Jin A; Xu Y; Liu S; Jin T; Li Z; Jin H; Lin L; Lin Z Exp Mol Pathol; 2014 Feb; 96(1):54-60. PubMed ID: 24263054 [TBL] [Abstract][Full Text] [Related]
17. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma. Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102 [TBL] [Abstract][Full Text] [Related]
18. Perioperative cytokine levels portend early death after pancreatectomy for ductal adenocarcinoma. Lewis HL; Chakedis JM; Talbert E; Haverick E; Rajasekera P; Hart P; Bloomston M; Dillhoff M; Pawlik TM; Guttridge D; Schmidt CR J Surg Oncol; 2018 May; 117(6):1260-1266. PubMed ID: 29205349 [TBL] [Abstract][Full Text] [Related]
20. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study. Distler M; Pilarsky E; Kersting S; Grützmann R Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]